businessbriefs
10:40in productionCh. 1 · What’s in a name?/ 10:40 · ceiling 15 min
Startups & venture

Amgen

1980

Amgen didn’t disrupt pharma — it proved that cloning one human gene at a time could build a billion-dollar company.

Amgen’s origin story is unusually concrete: founded in 1980, public by 1983, two gene-cloning projects yielding two FDA-approved drugs by 1991. No vague mission statements — just molecules, milestones, and money raised to get there.

Startups & ventureBiographyChemistryGeneticsBiography across the network →
Chapters & takeaways4
  1. 1:24
    What’s in a name?

    Amgen began as Applied Molecular Genetics — a name that signals its method, not its market.

  2. 2:56
    Capital before clones

    Its 1983 IPO raised nearly $40 million — not seed money, but fuel for a multi-year, high-risk molecular hunt.

  3. 5:00
    One gene, one drug

    Two genes, two teams, two years of lab work — erythropoietin first, then G-CSF — produced two drugs.

  4. 6:38
    Markets before medicine

    It licensed Epogen to Kirin in 1984, then waited two years for FDA approval of Neupogen — proving commercialisation was slower than discovery.

Worth your time?

Yes. Study the whole thing.

4.5/ 5
What works
  • gene cloning as product development
  • IPO timing relative to R&D phase
  • licensing as risk mitigation
  • FDA approval as commercial inflection point
What does not
  • revenue
  • pricing
  • manufacturing cost
  • reimbursement
Study it if
  • biotech founders
  • regulatory strategists
  • life-sciences investors
Skip it if
  • marketing executives
  • policy analysts
  • health economists
The written brief1 min read

What the company or idea is

Amgen is a biopharmaceutical company founded in April 1980 in Thousand Oaks, California, originally named Applied Molecular Genetics. It focuses on discovering, developing, and commercialising protein therapeutics using recombinant DNA technology.

How it actually makes money

Amgen makes money by developing and selling biopharmaceuticals — specifically, recombinant proteins — to treat serious diseases. It retains US distribution rights for its own products while licensing rights elsewhere, as with Kirin Brewery in Japan for Epogen.

What works

Cloning specific human genes (erythropoietin, G-CSF) and converting them into therapeutics worked. Securing FDA approval for Epogen in 1989 and Neupogen in 1991 worked. A joint venture with Kirin for Japanese distribution worked. Going public in 1983 to fund that work worked.

What does not

The material says nothing about revenue, margins, manufacturing cost, or patient access barriers. It does not establish whether Epogen or Neupogen achieved broad clinical adoption, nor whether Amgen controlled pricing or reimbursement.

What to take from it

Amgen’s early success came not from platform versatility or speed, but from sustained, targeted molecular work: two years to clone erythropoietin, then a year to clone G-CSF — each yielding one approved drug. Its business model was narrow, asset-specific, and dependent on regulatory milestones.

Is it worth your time

Yes — if you are studying how early biotech companies built commercial viability from gene cloning, not hype. Its 1983 IPO and two FDA-approved drugs by 1991 show a rare alignment of science, regulation, and capital before the sector matured.

Same desk · Startups & venture4 of 43
10:34
Enphase Energy2006Enphase Energy is a hardware-first energy technology company that built market position by solving a specific, observable failure in residential solar—central inverter underperformance—then scaling through successive generations of microinverters. Its business model relies entirely on third-party installers and distributors. It has no recurring revenue stream, no customer-facing software layer, and no ownership of energy generation. Its success reflects disciplined component-level innovation—not ecosystem control.
9:24
GenmabJan van de Winkel · 1998Genmab is a platform biotech — not a drug developer — built around two licensed and proprietary antibody generation methods. Its value is in reducing discovery risk and time, not in owning clinical or commercial outcomes.
12:25
Moderna2010Moderna is a vaccine company built on mRNA technology, validated in crisis, not sustained in market.
10:45
VolvoAssar Gabrielsson · 1927Volvo’s origin was not a corporate spin-off or investor-backed startup. It was a personal bet — financed by commissions saved in Paris, structured around a high-risk contract, validated by ten physical prototypes, and launched only after institutional rejection. Its early revenue came from trucks, not cars. Its founding story contradicts the myth of visionary consensus — it was a solo act of leverage, execution, and timing.
Up next in Business

Apollo Global Management

Leon Black · 1990 · 10:53

A firm built on exploiting financial collapse stayed solvent—but not its founder’s reputation.

Play nextBack to Startups & venture
10:53